Thromb Haemost 2000; 83(05): 785
DOI: 10.1055/s-0037-1613909
Letters to the Editor
Schattauer GmbH

Fast Decrease of Bleeding Time by Tranexamic Acid in Uremia

Diego Mezzano
1   From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile
,
Blanca Muñoz
1   From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile
,
Edgar Pais
1   From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile
,
Patricio Downey
1   From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile
,
Jaime Pereira
1   From the Departments of Hematology-Oncology and Nephrology, School of Medicine, Catholic University of Chile, Santiago, Chile
› Author Affiliations
Further Information

Publication History

Received 01 November 1999

Accepted after resubmission 05 January 2000

Publication Date:
08 December 2017 (online)

 

 
  • References

  • 1 Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 07: 107-17.
  • 2 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53.
  • 3 Mezzano D, Tagle R, Panes O, Pérez M, Downey P, Muñoz B, Aranda E, Barja P, Thambo S, González F, Mezzano S, Pereira J. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996; 76: 312-21.
  • 4 Mezzano D, Panes O, Pais E, Tagle R, González F, Mezzano S, Barriga F, Pereira J. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost 1999; 82: 1250-4.